علاج الورم الحبيبي مع التهاب الأوعية الدموية مع مرض مهدِّد للأعضاء أو مهدِّد للحياة

DOI: 10.1136/ard-2022-223764

• For induction of remission in patients with new-onset or relapsing GPA or MPA with organ-threatening or life-threatening disease, we recommend treatment with a combination of glucocorticoids and either rituximab or cyclophosphamide.
• Remission: Absence of typical signs, symptoms, or other features of active AAV with or without immunosuppressive therapy.
• Sustained remission: Absence of typical signs, symptoms, or other features of active AAV over a defined time period with or without immunosuppressive therapy.
• We recommend that therapy to maintain remission for GPA and MPA be continued for 24–48 months following induction of remission of new-onset disease.